TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM
Status:
Completed
Trial end date:
2017-09-29
Target enrollment:
Participant gender:
Summary
This is a dose-escalation study that will assess the safety and determine the maximum
tolerated dose (MTD) of mibefradil dihydrochloride, a partially selective T-type calcium
channel blocker, combined with hypofractionated radiation therapy (RT) in subjects with
recurrent glioblastoma multiforme (GBM).